Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

May 3, 2017

Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical Oncology's 53rd Annual Meeting 2017, taking place 2-6 June in Chicago. Isofol will present results from a study that demonstrates that there is an unmet clinical need of a superior rescue agent to be administrated after High Dose Methotrexate (HDMTX) treatment in osteosarcoma patients.

The abstract describes the findings from a retrospective observational study in osteosarcoma patients, from four different countries, treated with HDMTX as part of the standardised MAP treatment regime. The study objective was to determine to what extent patients treated with MAP encountered treatment delays due to MTX related toxicity or delayed MTX elimination. Full data has been submitted to the American Society of Clinical Oncology's 53rd Annual Meeting 2017.

Anders Rabbe, CEO of Isofol, says: "The study results are really interesting as they clearly show the frequent toxicity problems that lead to treatment delays in osteosarcoma patients when treated with the standard of care. This study highlights that there is a large unmet clinical need for a more effective HDMTX rescue treatment than today's golden standard, leucovorin."

HDMTX is a common therapeutic regimen in the treatment of osteosarcoma with folate-based therapies used as the golden standard to prevent treatment related high-dose toxicity. Isofol's lead candidate Modufolin® is currently being investigated as a novel and superior folate-based treatment for the same purpose.

Osteosarcoma

Osteosarcoma is a rare (accounting for 0.2% of all malignant tumours) primary malignant tumour of the skeleton. The mean annual incidence of osteosarcoma is 2.9 (range 1.5 – 4.0) per 1 000,000 in the European Economic Area (EEA) for the period 1998 to 2002. In comparison, the US across the entire SEER database, which covers over 26% of the US population, the annual incidence for the reporting period 1973 to 2004 is 3.1 per million.

For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
E-mail: anders.rabbe@isofolmedical.com
Phone: +46 (0)707 646 500

About Modufolin®

Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert it's effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in two clinical Phase II studies.

About Isofol Medical AB

Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck

KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofol.se

Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden